Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

被引：0
|
作者：
Yasuo Yanagi
Kanji Takahashi
Tomohiro Iida
Fumi Gomi
Junko Morii
Eriko Kunikane
Taiji Sakamoto
机构：
[1] Yokohama City University,Department of Ophthalmology and Microtechnology
[2] Kansai Medical University,Department of Ophthalmology
[3] Tokyo Women’s Medical University School of Medicine,Department of Ophthalmology
[4] Hyogo Medical University,Department of Ophthalmology
[5] IQVIA Solutions Japan,Department of Ophthalmology
[6] K.K.,undefined
[7] Senju Pharmaceutical Co.,undefined
[8] Ltd.,undefined
[9] Kagoshima University Graduate School of Medical and Dental Sciences,undefined
来源：
Ophthalmology and Therapy | 2023年 / 12卷
关键词：
Cost-effectiveness; Costs and cost analysis; Dosing regimens; Japan; Markov model; Neovascular age-related macular degeneration; Ranibizumab biosimilar; Societal perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2005 / 2021
页数：16
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GREECE
    Kourlaba, G.
    Tzanetakos, C.
    Datseris, J.
    Rouvas, A.
    Arzoumanidou, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [22] Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration
    Cohen, Salomon Yves
    Maloberti, Bertrand
    Fajnkuchen, Franck
    Nghiem-Buffet, Sylvia
    Delahaye-Mazza, Corinne
    Grenet, Typhaine
    Quentel, Gabriel
    OPHTHALMOLOGICA, 2014, 231 (02) : 80 - 85
  • [23] Ranibizumab for neovascular age-related macular degeneration - Reply
    Rosenfeld, Philip J.
    Brown, David M.
    Schneider, Susan
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 749 - 750
  • [24] The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
    Brown G.C.
    Brown M.M.
    Lieske H.B.
    Turpcu A.
    Rajput Y.
    International Journal of Retina and Vitreous, 3 (1)
  • [25] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN
    Clements, K. M.
    Hulbert, E. M.
    Panchmatia, H. R.
    Eriksson, M.
    Wittrup-Jensen, K. U.
    Nilsson, J.
    Weinstein, M. C.
    VALUE IN HEALTH, 2013, 16 (07) : A506 - A506
  • [26] Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
    Wang, Luping
    Zhang, Canwei
    Hua, Rui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3625 - 3633
  • [27] COST UTILITY ANALYSIS OF AFLIBERCEPT, RANIBIZUMAB, AND BEVACIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Lin, C. W.
    Hay, J.
    VALUE IN HEALTH, 2014, 17 (03) : A287 - A287
  • [28] COST-EFFECTIVENESS OF RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR WET AGE-RELATED MACULAR DEGENERATION (NAMD) AT THE MEXICAN SOCIAL SECURITY SYSTEM (IMSS)
    Arreola-Ornelas, H.
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Dorantes-Aguilar, J.
    Lemus-Carmona, E.
    VALUE IN HEALTH, 2012, 15 (04) : A251 - A251
  • [29] The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective
    van Asten, Freekje
    Michels, Charlotte T. J.
    Hoyng, Carel B.
    van der Wilt, Gert Jan
    Klevering, B. Jeroen
    Rovers, Maroeska M.
    Grutters, Janneke P. C.
    PLOS ONE, 2018, 13 (05):
  • [30] Treatment of neovascular age-related macular degeneration with Ranibizumab/LucentisTM
    Michels, S
    Rosenfeld, PJ
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2005, 222 (06) : 480 - 484
12345